Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Exacis Biotherapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","amount":"$49.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"N\/A","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"N\/A"}]

    Find Clinical Drug Pipeline Developments & Deals by Exacis Biotherapeutics

    Menu

    Exacis Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Exacis Biotherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

              Details:

              The acquisition includes global immuno-oncology platform of Exacis and its entire pipeline of engineered cell therapy programs for hematologic and solid tumors. Eterna will produce an unlimited number of mRNA-engineered NK and T-cell therapies derived from iPSCs.

              Lead Product(s): iPSC-based Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: N/A Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Eterna Therapeutics

              Deal Size: $49.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition May 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY